Search company, investor...

Novacea

Founded Year

2001

Stage

IPO | IPO

Total Raised

$100.84M

Date of IPO

5/10/2006

About Novacea

Novacea is a biopharmaceutical company that had been focused on in-licensing, developing and commercializing novel cancer therapies. Novacea has two product candidates, including AsentarTM, which had been in a Phase 3 clinical trial for androgen-independent prostate cancer, and AQ4N, a hypoxia-activated prodrug. There are currently no clinical trials planned or underway for either candidate.

Headquarters Location

400 Oyster Point Boulevard Suite 200

South San Francisco, California, 94080,

United States

650-228-1800

Missing: Novacea's Product Demo & Case Studies

Promote your product offering to tech buyers.

Reach 1000s of buyers who use CB Insights to identify vendors, demo products, and make purchasing decisions.

Missing: Novacea's Product & Differentiators

Don’t let your products get skipped. Buyers use our vendor rankings to shortlist companies and drive requests for proposals (RFPs).

Latest Novacea News

Novacea (NOVC) Prices IPO at $6.50/Sh

May 16, 2016

Join SI Premium – FREE Before the open, Novacea, Inc. (Nasdaq: NOVC ) announced that it priced its initial public offering of 6,250,000 shares of its common stock at a price to the public of $6.50 per share, which was below the $11-$13 range the company had expected. All of the shares of common stock are being offered by the Company. The shares are expected to open on the Nasdaq National Market today under the symbol "NOVC. " Bear, Stearns & Co. Inc. and Cowen and Company, LLC acted as joint book-running managers with Pacific Growth Equities, LLC and HSBC Securities (USA) Inc. as co-managers. Novacea has granted to the underwriters a 30-day option to purchase up to an additional 937,500 shares at the initial public offering price to cover over-allotments, if any. Novacea, Inc. is a biopharmaceutical company focused on in-licensing, developing and commercializing novel therapies for the treatment of cancer. Novacea's in-licensed product development programs include three clinical-stage oncology product candidates. The company has one product candidate, DN-101, which is in a Phase 3 clinical trial for prostate cancer and a second product candidate, vinorelbine oral, which is expected to enter into a registration trial in late 2006 for the treatment of metastatic breast cancer. Novacea's third product candidate, AQ4N, is expected to advance into a Phase 1/2 clinical trial in the second half of 2006 for the treatment of glioblastoma multiforme. You May Also Be Interested In

Novacea Frequently Asked Questions (FAQ)

  • When was Novacea founded?

    Novacea was founded in 2001.

  • Where is Novacea's headquarters?

    Novacea's headquarters is located at 400 Oyster Point Boulevard, South San Francisco.

  • What is Novacea's latest funding round?

    Novacea's latest funding round is IPO.

  • How much did Novacea raise?

    Novacea raised a total of $100.84M.

  • Who are the investors of Novacea?

    Investors of Novacea include New Enterprise Associates, Versant Ventures, Domain Associates, ProQuest Investments, Sofinnova Ventures and 3 more.

  • Who are Novacea's competitors?

    Competitors of Novacea include Gelesis, PDS Biotechnology, CureDM, Mast Therapeutics, Celator Pharmaceuticals and 13 more.

Compare Novacea to Competitors

S
Symphony Medical

Symphony Medical is a biopharmaceutical company focused on non-destructive treatments for cardiac conduction abnormalities using cellular-based or biopolymer-based therapies.

D
Deltanoid Pharmaceuticals

Deltanoid Pharmaceuticals is a clinical stage biopharmaceutical company with a vision focused on unlocking the power of the vitamin D receptor (VDR) to transform health outcomes for patients with diseases of the kidney, bone, and skin.

P
Pivotal Biosciences

Pivotal BioSciences, Inc. is a company focused on the development and commercialization of cancer therapies.

K
Kaperio

Kaperio is a biopharmaceutical company focused on cardiovascular disease.

a
aFraxis

Afraxis discover and develops drugs to treat diseases of the central nervous system, including schizophrenia, Alzheimer's disease, Fragile X syndrome and autism spectrum disorders. Recent scientific discoveries have linked these disorders to underlying defects in the development and function of specialized structures of the neural synapse, called dendritic spines. Afraxis is leveraging this discovery to develop drug treatments that control dendritic spine function. The company's lead program targets PAK, a protein that regulates the development and activity of dendritic spines, creating therapies that actually modify the disease rather than just treat symptoms. Modifying the disease produces beneficial changes at the cellular and behavioral level, creating new hope for patients.

N
Need Pharma

NeED Pharmaceuticals is a biopharmaceutical company focused on the discovery and development of anti-infective drugs for the treatment of serious and neglected infectious diseases, where a large unmet medical need and market opportunity are clearly present.

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.